2019 – AACR Annual Meeting (Atlanta) Eutropics presented a poster titled “Identifying Bcl-2 family protein dependencies in tumors using dimerization-specific antibody biomarkers as a method for predicting response to apoptosis-inducing therapies.” Eutropics
2018 – EHA23 (European Hematology Association) Data from a Phase II study of alvocidib plus cytarabine and mitoxantrone in relapsed/refractory AML (Zeidner et al.), where PraediCare Dx Noxa testing was used prospectively to identify MCL1 dependence as a functional biomarker; results showed that a majority of biomarker-selected patients achieved complete remission.eutropics
2016 – ASCO Annual Meeting (Chicago) Oral presentation: “Mitochondrial Profiling As a Predictive Biomarker for Response to Cytarabine-Based Treatment of Acute Myelogenous Leukemia” in the Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant session. biospace+1
2016 – AACR Annual Meeting (New Orleans) Poster: “Decitabine response in FLT3-negative AML is associated with mitochondrial priming,” Abstract Control #3432.eutropics
2015 – AACR Annual Meeting (Philadelphia) Poster: “Mitochondrial profiling in AML patients treated with an alvocidib-containing regimen reveals MCL-1 dependency in responder bone marrow,” presenting clinical correlation data on PraediCare Dx in AML.eutropics
2013 – ASCO Annual Meeting (Chicago) Eutropics announced a presentation on a personalized diagnostic for AML patient management (PraediCare Dx) at ASCO 2013, focused on using mitochondrial profiling to guide treatment decisions.
Share your love
Newsletter Updates
Enter your email address below and subscribe to our newsletter
